TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsNews
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 26.53 percent. This is a 37.93 percent increase over losses of $(0.29) per share
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 26.53 percent. This is a 37.93 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $2.567 million which beat the analyst consensus estimate of $2.048 million by 25.34 percent. This is a 286.02 percent increase over sales of $665.000 thousand the same period last year.